OverviewSuggest Edit
ImmuPharma is a pharmaceutical company focused on developing innovative drugs to treat serious medical conditions in specialist therapeutic areas. Its low risk-strategy is to work closely with the largest fundamental research institutions, which allows access to scientists and doctors, keeping costs low by avoiding the constant funding necessary for early-stage research. The Company offers Lupuzor, a treatment for Lupus and its most advanced drug candidate.
| Type | Public | |
| Founded | 1999 | |
| HQ | London, GB | Map |
| Website | immupharma.co.uk |
Recent NewsAll News
- Immupharma shares take off as firm signs US lupus deal
- The Life Sciences Division Update Report on ImmuPharma plc Post AstraZeneca plc Announcement of Anifrolumab Successfully Navigating a Second Phase III Clinical Trial in Lupus
- The Life Sciences Division Initiates Coverage on ImmuPharma Plc With a BUY/Corporate Rating
Key People/Management at ImmuPharma
Tim McCarthy
Non-Executive Chairman
Robert Zimmer
President, Chief Science Officer & Director
Dimitri F Dimitriou
Chief Executive Officer, Co-Founder & Director
Stéphane Méry
Non-Executive Director
Lisa Baderoon
Head of Investor Relations
Sylviane Muller
Research Director at CNRS & Co-Founder of ImmuPharma France
ImmuPharma Office Locations
ImmuPharma has offices in London, Mulhouse and Sarnen
London, GB (HQ)
50 Broadway
London, GB
1 Bartholomew Cl
Mulhouse, FR
5 Rue du Rhône
Sarnen, CH
10 Poststrasse
ImmuPharma Financials and Metrics
ImmuPharma Revenue
ImmuPharma's revenue was reported to be £81.28 k in FY, 2018
| GBP | |
|---|---|
Revenue (FY, 2018) | 81.3k |
Net income (FY, 2018) | (7.2m) |
EBITDA (FY, 2018) | (7.9m) |
EBIT (FY, 2018) | (8.1m) |
Market capitalization (16-Oct-2020) | 27.3m |
Closing stock price (16-Oct-2020) | 0.1 |
Cash (31-Dec-2018) | 4.9m |
EV | 22.5m |
ImmuPharma's current market capitalization is £27.3 m.
| GBP | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 25.4k | 63.2k | 57.1k | 22.1m | 32.5k | 16.8k | 184.8k | 76.4k | 164.8k | 150.5k | 81.3k | ||||
Revenue growth, % | (59%) | ||||||||||||||
Operating expense total | (1.5m) | 3.6m | 4.6m | 11.8m | 4.2m | (3.8m) | 3.6m | 4.6m | 6.8m | 7.4m | 8.2m | ||||
EBITDA | (2.0m) | (3.5m) | (4.5m) | 10.3m | (4.1m) | 3.9m | (4.1m) | (4.2m) | (3.3m) | (4.4m) | (6.5m) | (7.1m) | (7.9m) |
| GBP | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 1.0 | 1.0 | 1.0 | 978.2k | 1.0m | 2.7m | 2.9m | 12.5m | 22.5m | 15.6m | 12.2m | 8.9m | 5.4m | 5.4m | 833.4k | 1.9m | 2.7m | 4.9m |
Accounts Receivable | 3.2k | 22.2k | 2.8k | 13.2k | ||||||||||||||
Current Assets | 1.0 | 1.0 | 1.0 | 979.9k | 1.0m | 2.9m | 3.3m | 12.6m | 23.9m | 16.8m | 13.5m | 9.8m | 6.5m | 6.1m | 2.4m | 6.0m | 4.4m | 6.0m |
PP&E | 12.0k | 12.8k | 13.3k | 9.3k | 76.8k | 125.4k | 114.8k | 97.1k | 366.4k | 280.1k | 231.9k | 161.4k | 164.7k |
| GBP | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.4k | 15.1k | (2.5m) | (3.1m) | 4.7m | 8.1m | (2.0m) | (3.4m) | (3.8m) | (3.7m) | (2.9m) | (3.9m) | (5.3m) | (6.2m) | (7.2m) |
Cash From Operating Activities | 15.8k | 18.3k | 879.6k | 3.8m | (3.6m) | 12.0m | (6.8m) | (3.4m) | (3.3m) | (3.9m) | (2.5m) | (4.1m) | (6.5m) | (4.4m) | (4.7m) |
Cash From Financing Activities | 977.0k | 3.0m | (77.6k) | 12.0m | (143.5k) | 555.2k | 165.3k | 356.9k | 191.5k | 3.0m | (310.1k) | 7.4m | 5.4m | 9.1m | |
Net Change in Cash | 978.2k | 27.1k | 2.7m | 3.7m | 8.5m | 11.9m | (6.4m) | (3.2m) | (2.8m) | (3.7m) | 199.0k | (4.5m) | 896.3k | 945.9k | 2.3m |
| GBP | FY, 2001 |
|---|---|
Financial Leverage | 1 x |
ImmuPharma Cybersecurity Score
ImmuPharma Online and Social Media Presence
520 Twitter followers
ImmuPharma has 520 Twitter Followers. The number of followers has increased 1.2% month over month and increased 2.4% quarter over quarter
ImmuPharma's Trends
Twitter Engagement Stats for @ImmuPharma
72
Tweets
57
Following
520
Followers
2
Tweets last 30 days
1
Avg. likes per Tweet
100%
Tweets with engagement
ImmuPharma News and Updates
November 28, 2019
Immupharma shares take off as firm signs US lupus deal
Specialist drug developer Immupharma rose almost 300 per cent today on the back of an exclusive US licensing deal for [...]
The post Immupharma shares take off as firm signs US lupus deal appeared first on CityAM.
September 09, 2019
The Life Sciences Division Update Report on ImmuPharma plc Post AstraZeneca plc Announcement of Anifrolumab Successfully Navigating a Second Phase III Clinical Trial in Lupus
LONDON, Sept. 9, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces an update report on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on...
May 28, 2019
The Life Sciences Division Initiates Coverage on ImmuPharma Plc With a BUY/Corporate Rating
LONDON, May 28, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces the initiation of research on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on ...
ImmuPharma Blogs
September 09, 2020
Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $200,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertibl…
September 08, 2020
Director/PDMR Shareholding/TR-1
To download click here
The post Director/PDMR Shareholding/TR-1 appeared first on ImmuPharma.
September 07, 2020
Placing to raise £6.5 million – update; related party transaction
The Company announces that admission of the Placing Shares issued in the Placing (as defined in the announcement of 2 September 2020) which was expected to take place at 8.00am on or around 7 September 2020 is now expected to take place at 8.00 am on Tuesday 8 September. The Company also announces i…
September 03, 2020
Conversion of Convertible Security
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $150,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertibl…
September 02, 2020
Placing to raise £6.5 million
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that in response to investor demand, it has raised £6.5 million, before expenses, via an oversubscribed Placing of 59,090,909 new ordinary shares of 10p each in the Company (“…
July 27, 2020
Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients
ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an important regulatory milestone in preparation for the new optimised international Phase III trial of Lupuzor™ for systemic lupus erythematosus (“SLE”) a potentially life-t…
ImmuPharma Frequently Asked Questions
When was ImmuPharma founded?
ImmuPharma was founded in 1999.
Who are ImmuPharma key executives?
ImmuPharma's key executives are Tim McCarthy, Robert Zimmer and Dimitri F Dimitriou.
How many employees does ImmuPharma have?
ImmuPharma has 17 employees.
What is ImmuPharma revenue?
Latest ImmuPharma annual revenue is £81.3 k.
What is ImmuPharma revenue per employee?
Latest ImmuPharma revenue per employee is £4.8 k.
Who are ImmuPharma competitors?
Competitors of ImmuPharma include Bracco, Advanced Accelerator Applications and Akrivis Technologies.
Where is ImmuPharma headquarters?
ImmuPharma headquarters is located at 50 Broadway, London.
Where are ImmuPharma offices?
ImmuPharma has offices in London, Mulhouse and Sarnen.
How many offices does ImmuPharma have?
ImmuPharma has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies